Scilex Holding (SCLX) EBIT Margin (2022 - 2026)
Scilex Holding (SCLX) posted quarterly EBIT Margin of 374.06% for Q1 2026, up 18390.0% year-over-year from N/an in Q1 2025, and up 83.7% on a QoQ basis from 2295.25% in Q4 2025.
Scilex Holding (SCLX) EBIT Margin (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported EBIT Margin for 5 consecutive years, with 374.06% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin rose 18390.0% year-over-year to 374.06%; the TTM figure through Mar 2026 stood at 1033.39% (down 85232.0% YoY), while the FY2025 annual figure was 1141.94%, down 99457.0% from the prior year.
- EBIT Margin came in at 374.06% for Q1 2026 at Scilex Holding, up from 2295.25% in the prior quarter.
- The five-year high for EBIT Margin was 93.31% in Q3 2022, with the low at 2295.25% in Q4 2025.
- Average EBIT Margin over 5 years is 428.13%, with a median of 181.32% recorded in 2023.
- Across the five-year window, EBIT Margin soared 24559 bps in 2024 and plunged 210479 bps in 2025, its largest moves.
- Year by year, EBIT Margin stood at 165.63% in 2022, then grew by 18 bps to 136.23% in 2023, then plunged by 40 bps to 190.46% in 2024, then plunged by 1105 bps to 2295.25% in 2025, then soared by 84 bps to 374.06% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 374.06%, 2295.25%, and 1766.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 47.98% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 26.44% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 26.60% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.51% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -286.83% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -374.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -374.06% |
| Dec 31, 2025 | -2,295.25% |
| Sep 30, 2025 | -1,766.21% |
| Jun 30, 2025 | -207.23% |
| Mar 31, 2025 | -557.96% |
| Dec 31, 2024 | -190.46% |
| Sep 30, 2024 | -137.97% |
| Jun 30, 2024 | -95.44% |
| Mar 31, 2024 | -178.96% |
| Dec 31, 2023 | -136.23% |
| Sep 30, 2023 | -383.56% |
| Jun 30, 2023 | -181.32% |
| Mar 31, 2023 | -240.72% |
| Dec 31, 2022 | -165.63% |
| Sep 30, 2022 | -93.31% |
| Jun 30, 2022 | -144.73% |
| Mar 31, 2022 | -129.27% |